A phase III pivotal, multicenter, double-blind, randomized, placebo-controlled study of milnacipran for the treatment of fibromyalgia

Trial Profile

A phase III pivotal, multicenter, double-blind, randomized, placebo-controlled study of milnacipran for the treatment of fibromyalgia

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2013

At a glance

  • Drugs Milnacipran (Primary)
  • Indications Fibromyalgia; Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 20 May 2009 Additional reference added (1132643) relating to published results from 162nd Annual Meeting of the American Psychiatric Association.
    • 07 May 2009 Results presented at the 28th Annual Scientific Meeting of the American Pain Society (APS 2009).
    • 14 Jan 2009 Results of this study supported the US FDA aproval of the agent under the trade name Savella.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top